7 November 2016 - The recent Lancet Editorial on the High Court ruling that rejected NHS England's decision not to provide HIV pre-exposure prophylaxis (PrEP) reflected upon the difficult choices facing policy makers forced to choose between effectiveness and affordability in health interventions.

Citing PrEP's efficacy despite its high price, alongside ballooning costs of diabetes and cancer, the editorial asked whether NHS funding should be increased. This is an important question. But we must also ask: do pharmaceutical corporations get a larger share of the funding than they should?

Read The Lancet article